Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis

Mari Gotoh, Yuko Fujiwara, Junming Yue, Jianxiong Liu, Sue Lee, James Fells, Ayako Uchiyama, Kimiko Murakami-Murofushi, Stephen Kennel, Jonathan Wall, Renukadevi Patil, Renuka Gupte, Louisa Balazs, Duane Miller, Gabor Tigyi

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate LPA. In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalBiochemical Society Transactions
Volume40
Issue number1
DOIs
StatePublished - Feb 1 2012

Fingerprint

Lysophosphatidic Acid Receptors
Lysophosphatidylcholines
Choline
Scaffolds
Serine
Intercellular Signaling Peptides and Proteins
Phosphates
Cells
Lipids
Fluids
Neoplasms
Therapeutics
lysophosphatidylserine
alkylglycerophosphoethanolamine phosphodiesterase
lysophosphatidic acid

All Science Journal Classification (ASJC) codes

  • Biochemistry

Cite this

Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. / Gotoh, Mari; Fujiwara, Yuko; Yue, Junming; Liu, Jianxiong; Lee, Sue; Fells, James; Uchiyama, Ayako; Murakami-Murofushi, Kimiko; Kennel, Stephen; Wall, Jonathan; Patil, Renukadevi; Gupte, Renuka; Balazs, Louisa; Miller, Duane; Tigyi, Gabor.

In: Biochemical Society Transactions, Vol. 40, No. 1, 01.02.2012, p. 31-36.

Research output: Contribution to journalReview article

Gotoh, Mari ; Fujiwara, Yuko ; Yue, Junming ; Liu, Jianxiong ; Lee, Sue ; Fells, James ; Uchiyama, Ayako ; Murakami-Murofushi, Kimiko ; Kennel, Stephen ; Wall, Jonathan ; Patil, Renukadevi ; Gupte, Renuka ; Balazs, Louisa ; Miller, Duane ; Tigyi, Gabor. / Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis. In: Biochemical Society Transactions. 2012 ; Vol. 40, No. 1. pp. 31-36.
@article{b5a48826121c41d58199dc124fcbb322,
title = "Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis",
abstract = "LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate LPA. In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.",
author = "Mari Gotoh and Yuko Fujiwara and Junming Yue and Jianxiong Liu and Sue Lee and James Fells and Ayako Uchiyama and Kimiko Murakami-Murofushi and Stephen Kennel and Jonathan Wall and Renukadevi Patil and Renuka Gupte and Louisa Balazs and Duane Miller and Gabor Tigyi",
year = "2012",
month = "2",
day = "1",
doi = "10.1042/BST20110608",
language = "English (US)",
volume = "40",
pages = "31--36",
journal = "Biochemical Society Transactions",
issn = "0300-5127",
publisher = "Portland Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis

AU - Gotoh, Mari

AU - Fujiwara, Yuko

AU - Yue, Junming

AU - Liu, Jianxiong

AU - Lee, Sue

AU - Fells, James

AU - Uchiyama, Ayako

AU - Murakami-Murofushi, Kimiko

AU - Kennel, Stephen

AU - Wall, Jonathan

AU - Patil, Renukadevi

AU - Gupte, Renuka

AU - Balazs, Louisa

AU - Miller, Duane

AU - Tigyi, Gabor

PY - 2012/2/1

Y1 - 2012/2/1

N2 - LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate LPA. In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.

AB - LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate LPA. In the present article, we review some of the key findings that make the ATX-LPA signalling axis an emerging target for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84863011845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863011845&partnerID=8YFLogxK

U2 - 10.1042/BST20110608

DO - 10.1042/BST20110608

M3 - Review article

VL - 40

SP - 31

EP - 36

JO - Biochemical Society Transactions

JF - Biochemical Society Transactions

SN - 0300-5127

IS - 1

ER -